$BOTY
LINGERIE FIGHTING CHAMPIONSHIPS, INC.

2023 Q3 Form 10-Q Financial Statement

#000164033423001324 Filed on July 18, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q1 2022 Q4
Revenue $32.46K $25.20K $34.97K
YoY Change 27.81% 19.06% 83.09%
Cost Of Revenue $10.45K $24.85K $9.170K
YoY Change 7.73% -69.01%
Gross Profit $22.01K $350.00 $25.80K
YoY Change 40.23% -98.35% -345.95%
Gross Profit Margin 67.8% 1.39% 73.78%
Selling, General & Admin $92.23K $60.70K $64.97K
YoY Change 25.09% -24.89% -66.71%
% of Gross Profit 419.11% 17342.86% 251.82%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $92.23K $60.70K $64.98K
YoY Change 25.09% -24.89% -66.7%
Operating Profit -$70.22K -$60.35K -$39.18K
YoY Change 20.99% 1.18% -80.95%
Interest Expense $65.90K -$11.77K $743.9K
YoY Change -13.64% -110.46% -90.91%
% of Operating Profit
Other Income/Expense, Net -$555.1K -$11.77K
YoY Change -9.48% -101.36%
Pretax Income -$625.4K -$72.13K $704.7K
YoY Change -6.84% -108.97% -91.16%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$625.4K -$72.13K $704.7K
YoY Change -6.84% -108.97% -91.16%
Net Earnings / Revenue -1926.82% -286.23% 2015.1%
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 3.712B shares 3.712B shares 3.535B shares
Diluted Shares Outstanding 10.20B shares 11.26B shares

Balance Sheet

Concept 2023 Q3 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.150K $810.00 $10.01K
YoY Change -74.98% -94.53% -70.97%
Cash & Equivalents $3.153K $810.00 $10.01K
Short-Term Investments
Other Short-Term Assets $0.00
YoY Change -100.0%
Inventory
Prepaid Expenses $0.00
Receivables
Other Receivables
Total Short-Term Assets $3.153K $810.00 $10.01K
YoY Change -84.3% -96.37% -76.16%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets -$3.00 $0.00 $0.00
YoY Change -175.0% -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $3.153K $810.00 $10.01K
Total Long-Term Assets -$3.00 $0.00 $0.00
Total Assets $3.150K $810.00 $10.01K
YoY Change -84.32% -96.37% -76.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $652.7K $605.9K $579.8K
YoY Change 1303.05% 25.54% 24.64%
Accrued Expenses $608.5K $497.1K $442.9K
YoY Change 56.58% 75.93% 91.03%
Deferred Revenue
YoY Change
Short-Term Debt $1.021M $967.1K $924.7K
YoY Change 13.4% 12.25% 15.62%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.032M $4.978M $4.915M
YoY Change -12.43% -17.28% -28.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.032M $4.978M $4.915M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $5.032M $4.978M $4.915M
YoY Change -12.43% -17.28% -28.16%
SHAREHOLDERS EQUITY
Retained Earnings -$10.07M -$9.943M
YoY Change -5.45% -15.17%
Common Stock $3.712M $3.712M
YoY Change 4.99% 4.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.029M -$4.977M -$4.905M
YoY Change
Total Liabilities & Shareholders Equity $3.153K $810.00 $10.01K
YoY Change -84.3% -96.37% -76.16%

Cashflow Statement

Concept 2023 Q3 2023 Q1 2022 Q4
OPERATING ACTIVITIES
Net Income -$625.4K -$72.13K $704.7K
YoY Change -6.84% -108.97% -91.16%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$61.70K -$35.10K -$21.09K
YoY Change 371.35% 78.32% -77.83%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 61.44K 25.90K 18.52K
YoY Change -70.83%
NET CHANGE
Cash From Operating Activities -61.70K -35.10K -21.09K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 61.44K 25.90K 18.52K
Net Change In Cash -260.0 -9.200K -2.570K
YoY Change -98.01% -53.26% -91.88%
FREE CASH FLOW
Cash From Operating Activities -$61.70K -$35.10K -$21.09K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
584730 usd
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001407704
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
51 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
51 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3711714036 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3711714036 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3711714036 shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2022 boty Redeemed Per Share
RedeemedPerShare
0
CY2023Q1 boty Redeemed Per Share
RedeemedPerShare
0
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5637133523 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
76307 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
174984 usd
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
8032 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
89183 usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
000-55498
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
LINGERIE FIGHTING CHAMPIONSHIPS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8009362
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
6955 North Durango Drive
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1115-129
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89149
CY2023Q1 dei City Area Code
CityAreaCode
702
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
505-0743
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3711714036 shares
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10009 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
10009 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
37098 usd
CY2023Q1 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
568568 usd
CY2022Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
542668 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
442888 usd
CY2023Q1 boty Promissory Notes Payable Current
PromissoryNotesPayableCurrent
365000 usd
CY2022Q4 boty Promissory Notes Payable Current
PromissoryNotesPayableCurrent
340000 usd
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
17412 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
34800 usd
CY2022Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
584730 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2967243 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4914627 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
51 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3711714036 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3711715 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1327104 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9943437 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4904618 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10009 usd
CY2023Q1 boty Cost Of Service
CostOfService
24846 usd
CY2022Q1 boty Cost Of Service
CostOfService
0 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
349 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
21165 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18104 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14912 usd
CY2023Q1 boty Professional Fee
ProfessionalFee
12598 usd
CY2022Q1 boty Professional Fee
ProfessionalFee
35900 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
60702 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
80812 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-60353 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-59647 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
71583 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
112491 usd
CY2023Q1 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
59810 usd
CY2022Q1 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
976124 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11773 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
863633 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-72126 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
803986 usd
CY2023Q1 boty Earnings Per Shares Basic And Diluted1
EarningsPerSharesBasicAndDiluted1
-0.00
CY2022Q1 boty Earnings Per Shares Basic And Diluted1
EarningsPerSharesBasicAndDiluted1
0.00
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2023Q1 boty Basic And Diluted Weighted Average Shares Of Common Stock Outstanding
BasicAndDilutedWeightedAverageSharesOfCommonStockOutstanding
3711714036 shares
CY2022Q1 boty Basic And Diluted Weighted Average Shares Of Common Stock Outstanding
BasicAndDilutedWeightedAverageSharesOfCommonStockOutstanding
3535302536 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11262253844 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9668593425 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4904618 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-72126 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4976744 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-6798809 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
803985 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-5994824 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-72126 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
803985 usd
CY2023Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-59810 usd
CY2022Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-976124 usd
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
61786 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
25000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
251 usd
CY2023Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
54194 usd
CY2022Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
50705 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35102 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
900 usd
CY2022Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
CY2023Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
25000 usd
CY2022Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-9202 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-19684 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14797 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Lingerie Fighting Championships, Inc. (the “Company”) is a Nevada corporation incorporated on November 29, 2006 under the name Sparking Events, Inc. The Company’s corporate name was changed to Xodtec Group USA, Inc. in June 2009, Xodtec LED, Inc. in May 2010, Cala Energy Corp. in September 2013 and Lingerie Fighting Championships, Inc. on April 1, 2015.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company focuses on developing, producing, promoting, and distributing entertainment through live entertainment events, digital home videos, broadcast television networks, video on demand, and digital media channels in the United States. It offers wrestling and mixed martial arts fights featuring women under the LFC brand name.</p>
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company continually evaluates its estimates and judgments. The Company bases its estimates and judgments on historical experience and other factors that it believes to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known, even for estimates and judgments that are not deemed critical.</p>
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
807 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10009 usd
CY2023Q1 us-gaap Revenues
Revenues
25195 usd
CY2022Q1 us-gaap Revenues
Revenues
21165 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
24846 usd
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
349 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
21165 usd
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7550539808 shares
CY2022Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6133290889 shares
CY2023Q1 boty Related Party Balances And Transactionspolicytextblock
RelatedPartyBalancesAndTransactionspolicytextblock
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company follows FASB ASC 850, “<em>Related Party Disclosures</em>,” for the identification of related parties and disclosure of related party transaction. (See Note 9)</p>
CY2023Q1 us-gaap Derivative Assets
DerivativeAssets
0 usd
CY2023Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
2907433 usd
CY2022Q4 us-gaap Derivative Assets
DerivativeAssets
0 usd
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
2967243 usd
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
51 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
51 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3711714036 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.0001
CY2022 boty Number Of Shares Granted
NumberOfSharesGranted
282080000 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.0005
CY2022 boty Exercised
Exercised
-201613143 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.0001
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5637133523 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.0001
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5637133523 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.0001
CY2023Q1 boty Expected Term
ExpectedTerm
P2Y8M1D
CY2022Q1 boty Expected Term
ExpectedTerm
P3Y6M18D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
976677 usd
CY2023Q1 boty Closing Market Price
ClosingMarketPrice
0.0003
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5637133523 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1642540 shares
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1683773 shares
CY2023Q1 boty Schedule Of Promissory Notes Payable
ScheduleOfPromissoryNotesPayable
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Promissory Notes to Auctus Fund</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">365,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">340,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total Promissory Notes</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">365,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">340,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2023Q1 boty Promissory Notes To Auctus Fund
PromissoryNotesToAuctusFund
365000 usd
CY2022Q4 boty Promissory Notes To Auctus Fund
PromissoryNotesToAuctusFund
340000 usd
CY2023Q1 us-gaap Notes Payable
NotesPayable
365000 usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
340000 usd
CY2021Q1 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
35000 usd
CY2021Q1 boty Warrants Derivative Amount
WarrantsDerivativeAmount
265000 usd
CY2021Q1 boty Debt Instrument Aggregate Discount
DebtInstrumentAggregateDiscount
300000 usd
CY2021Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
248077 usd
CY2021Q4 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
9000 usd
CY2021Q4 boty Warrants Derivative Amount
WarrantsDerivativeAmount
31000 usd
CY2021Q4 boty Debt Instrument Aggregate Discount
DebtInstrumentAggregateDiscount
40000 usd
CY2021Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
2740 usd
CY2023Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
602119 usd
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
2967243 usd
CY2023Q1 boty Gain On Change In Fair Value Of The Derivative
GainOnChangeInFairValueOfTheDerivative
-59810 usd
CY2023Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
2907433 usd
CY2023Q1 boty Gain Loss On Change In Fair Value Of Derivative Liabilities On Convertible Notes And Warrants
GainLossOnChangeInFairValueOfDerivativeLiabilitiesOnConvertibleNotesAndWarrants
-59810 usd
CY2022Q1 boty Gain Loss On Change In Fair Value Of Derivative Liabilities On Convertible Notes And Warrants
GainLossOnChangeInFairValueOfDerivativeLiabilitiesOnConvertibleNotesAndWarrants
-976124 usd
CY2023Q1 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-59810 usd
CY2022Q1 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-976124 usd
CY2023Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
568568 usd
CY2022Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
542668 usd

Files In Submission

Name View Source Status
0001640334-23-001324-index-headers.html Edgar Link pending
0001640334-23-001324-index.html Edgar Link pending
0001640334-23-001324.txt Edgar Link pending
0001640334-23-001324-xbrl.zip Edgar Link pending
boty-20230331.xsd Edgar Link pending
boty_10q.htm Edgar Link pending
boty_ex311.htm Edgar Link pending
boty_ex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
boty-20230331_cal.xml Edgar Link unprocessable
boty-20230331_def.xml Edgar Link unprocessable
boty-20230331_lab.xml Edgar Link unprocessable
boty-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
boty_10q_htm.xml Edgar Link completed
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending